Dr. Fischbach's laboratory uses a combination of genomics and chemistry to identify and characterize small molecules from microbes, with an emphasis on the human microbiome.

The Myung Research Group is a translational laboratory focused on two areas of clinical need: ophthalmic regenerative medicine through tissue engineering and drug delivery; and global health through mobile technologies and telemedicine.

The Zuchero Lab aims to uncover how glial cells regulate neural development and how their dysfunction contributes to diseases like multiple sclerosis (MS) and in injuries like stroke.

Dr. Chiu's research is the development of methodology for electron cryo-microscopy to determine 3D structures of macromolecules, molecular machines, organelles and cells.

Dr. Jagannathan is an Infectious Diseases specialist with 7 years of experience in translational immunology research focused on pathogen-specific cellular immune responses.

Dr. Beadle's research goals are to improve the outcomes of patients diagnosed with head and neck cancer through the integration of novel agents with radiation therapy, understanding key molecular drivers of the disease, and optimizing the use of advanced computational and physics-based approaches to improve treatment planning.

Dr. Moss's aim is to develop non-invasive structural and functional markers of papilledema physiology that predict visual outcomes in idiopathic intracranial hypertension (IIH) and guide tailored intervention that will improve visual outcomes and prevent blindness.

The Kaltschmidt lab’s goal is to understand the molecular basis of neuronal circuit formation. They are particularly interested in circuits that underlie locomotion, sexual function and gut motility.

Dr. Vilches-Moure's collaborative research interests include: developmental biology, cardiac biology, cardiac development, cardiac pathology, developmental pathology, and pathology of laboratory animal species, and his main goal is to provide collaborative pathology support to investigators who use models of disease.

The goal of Dr. Nuyujukian's work is to develop brain-machine interfaces as a platform technology for a variety of brain-related medical conditions including stroke and epilepsy.